Abbott's Alinity s gets FDA green light for hepatitis C

2019 02 13 19 24 5396 Fda Logo V2 400

The U.S. Food and Drug Administration (FDA) approved a biologics license application (BLA) on July 9 for Abbott's Alinity s chemiluminescent microparticle immunoassay for detecting antibodies to the hepatitis C virus in human serum and plasma specimens.

The BLA covers the use of hepatitis C virus-encoded antigens for screening individual donors, including volunteer donors, of whole blood and blood components and living donors for the presence of the hepatitis C virus.

The Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems, Abbott noted in a statement on July 11.

Page 1 of 2
Next Page